FNDR-20123 free base 是一种有效、安全、首创的抗疟疾HDAC抑制剂,对疟原虫和人类 HDAC 的IC50分别为 31 nM 和 3 nM。FNDR-20123 free base 对恶性疟原虫 (Plasmodium falciparum) 无性期 (IC50=41 nM) 和性血期 (雄性配子体 IC50=190 nM) 具有抗疟疾活性。FNDR-20123 free base 抑制 HDAC1,HDAC2,HDAC3,HDAC6,HDAC8 的 IC50分别为 25,29,2,11,282 nM,并在纳摩尔浓度下抑制 III 类 HDAC 亚型。
生物活性 | FNDR-20123 free base is a safe, first-in-class, and orally active anti-malarialHDACinhibitor withIC50s of 31 nM and 3 nM forPlasmodiumand humanHDAC, respectively. FNDR-20123 free base exerts anti-malarial activity againstPlasmodiumfalciparumasexual stage (IC50=41 nM) and sexual blood stage (IC50=190 nM for male gametocytes). FNDR-20123 free base inhibitsHDAC1,HDAC2,HDAC3,HDAC6, andHDAC8(IC50=25, 29, 2, 11, and 282 nM, respectively) and inhibits Class IIIHDACisoforms at nanomolar concentrations[1]. |
IC50& Target[1] | human HDAC 3 nM (IC50) | PlasmodiumHDAC 31 nM (IC50) | HDAC1 25 nM (IC50) | HDAC2 29 nM (IC50) | HDAC3 2 nM (IC50) | HDAC6 11 nM (IC50) | HDAC8 282 nM (IC50) | Plasmodium |
|
体外研究 (In Vitro) | FNDR-20123 is active against all resistant strains tested so far, which will be highly valuable in eliminating the rapidly evolving drug-resistant parasite[1].
|
体内研究 (In Vivo) | FNDR-20123 (10-50 mg/kg; p.o.; bw for 4 days) is also able to reduce parasitaemia significantly in a mouse model for P. falciparum infection[1].
Animal Model: | P. falciparum Pf3D70087/N9in NODscidIL2Rγnullmice (engrafted with human erythrocytes)[1] | Dosage: | 10 and 50 mg/kg | Administration: | P.o.; bw for 4 days | Result: | Resulted in a significant reduction in parasitaemia with 6.5% and 2.57% parasitaemia at 10 and 50 mg/kg, respectively. |
|
分子量 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
溶解性数据 | In Vitro: DMSO : 35.71 mg/mL(94.61 mM;Need ultrasonic) 配制储备液 1 mM | 2.6494 mL | 13.2471 mL | 26.4943 mL | 5 mM | 0.5299 mL | 2.6494 mL | 5.2989 mL | 10 mM | 0.2649 mL | 1.3247 mL | 2.6494 mL |
In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: 2.08 mg/mL (5.51 mM); Suspended solution; Need ultrasonic
此方案可获得 2.08 mg/mL (5.51 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.08 mg/mL (5.51 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (5.51 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.08 mg/mL (5.51 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (5.51 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|